Omicron: Pfizer/BioNTech, Moderna hopes to have variant vaccine data soon
FRANKFURT – BioNTech SE on Friday said it hopes to have more data on a disturbing new coronavirus variant discovered in South Africa within two weeks to help determine whether a vaccine was made with a partner. Does Pfizer Inc have to be remade?
Pfizer and BioNTech said that if needed, they expect to be able to ship a new vaccine tailored to the emerging variant in about 100 days.
BioNTech said in a statement when asked for comment: “We understand the concerns of the experts and have immediately begun investigations into variant B.1.1.529.
“We expect more data from laboratory trials in at least two weeks. These data will provide more information on whether B.1.1.529 could be an exit variant. dangerous and may require adjustments to our vaccine if this variant spreads globally,” it added.
Moderna Inc said in a statement that it is working to promote a suitable booster candidate for the new variant and has also been testing higher doses of its existing enhancer and to study the Other enhancement candidates are designed to protect against multiple variations.
“A booster dose of an authorized vaccine represents the only strategy currently available to boost attenuated immunity,” Moderna said in the statement.
Escape variants are those that suppress the targeted immune response brought on by vaccination. Pfizer and BioNTech will be able to redesign their footage within six weeks and deliver the first batches within 100 days, BioNTech added.
BioNTech ADRs rose 14.2% to close at $348 on Friday, and Pfizer stock rose 6.1% to end at $54. Moderna rose 20.6% to close at $329.63.
Global authorities responded to Friday’s warning with a new variant, with the EU and UK among those tightening border controls as scientists seek to find out if the mutation is resistant vaccine or not.
Pfizer and BioNTech have created versions of their established mRNA-based vaccines – based on the original virus found in the Chinese city of Wuhan – to target so-called variants. Alpha and Delta, with ongoing clinical trials.
Such efforts are not intended to yield a commercial product; exercise is done to establish a routine with regulators that will help speed up any future vaccine relaunch.
Analysts at Evercore ISI say data from Qatar on another recent variant shows that the initial high levels of effectiveness of current vaccines have significantly decreased four months after administration.
Johnson and Johnson said they are also closely monitoring emerging strains of COVID-19 and are testing the effectiveness of firing it against the new variant.
(Reporting by Ludwig Burger in Frankfurt; Additional reporting by Carl O’Donnell in New York; Editing by Kirsten Donovan and Matthew Lewis)